Breathe Well Live Well
FiercePharma |
PhIII data puts AZ one step closer to severe-asthma showdown with GSK
FiercePharma Last week, the British drugmaker announced that its candidate for severe asthma with eosinophilic inflammation–benralizumab–had nailed its primary endpoint in two Phase III studies, beating out placebo at paring down the annual asthma exacerbation … |
View full post on asthma – Google News
Reuters |
Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII
FierceBiotech Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development … Sanofi's dual-action biotech asthma drug performs well in test Positive results for Sanofi/Regeneron's dupilumab in asthma |
View full post on asthma – Google News
Reuters UK |
AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown
FierceBiotech Receptos, meanwhile, in-licensed an IL-13 drug from AbbVie after the pharma company decided to de-prioritize its respiratory efforts, including a program for asthma. Receptos is testing RPC4046 for Eosinophilic esophagitis, an orphan disease, and … AstraZeneca starts final-stage tests on severe asthma drug AstraZeneca share price: Drugmaker starts late-stage asthma drug trial AZ severe asthma drug tralokinumab goes into Phase III |
View full post on asthma – Google News
 World First Travel Insurance |
GSK asthma drug cuts symptoms 52%; ready for PhIII
Pharma Times GlaxoSmithKline's mepolizumab is now ready for late-stage testing after turning in a strong performance in Phase II trials assessing the experimental drug in a rare and hard-to-treat form of asthma. The Phase IIb trial was designed to investigate … GSK drug halves attacks in hard-to-treat asthma Drug 'could cut asthma A&E visits' Experimental Asthma Drug Halves Attacks |
View full post on asthma – Google News
|
GSK runs to PhIII with upbeat data on drug for severe asthma
FierceBiotech GlaxoSmithKline ($GSK) generated positive results from a mid-stage trial for its experimental drug in patients with an uncommon form of asthma, giving the London drug giant confidence in advancing the program to Phase III development before the end of … |
View full post on asthma – Google News